Gemcitabine: monochemotherapy of breast cancer.
Gemcitabine is a nucleoside analogue with proven activity in advanced and metastatic breast cancer. Its action is associated with a favourable toxicity profile which is mainly hematological. Its unique mechanism of action along with not overlapping toxicity is particularly useful both in combination treatment with other active drugs and a sequential therapy in the palliative setting. Phase II studies of gemcitabine performed over the last decade were reviewed. Despite some conflicting results in some trials, gemcitabine confirmed to be a useful drug to treat this condition.